Does Rallies show 13F holders for BMRN?

Yes. Rallies tracks hedge fund and 13F ownership data for BMRN, including fund names, share counts, latest tracked quarter, and position changes when available.

Is BMRN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BMRN. It does not provide personalized investment advice.

BMRN (BioMarin Pharmaceuticals Inc) Stock Analysis - Hedge Fund Holdings

BioMarin Pharmaceuticals Inc (BMRN) is a publicly traded Healthcare sector company. As of May 20, 2026, BMRN trades at $52.02 with a market cap of $9.60B and a P/E ratio of 35.90. BMRN moved +0.76% today. Year to date, BMRN is -16.22%; over the trailing twelve months it is -16.16%. Its 52-week range spans $49.26 to $73.51. Analyst consensus is buy with an average price target of $89.31. Rallies surfaces BMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns BMRN stock?

Hedge funds tracked by Rallies that own BMRN include Viking Global, Elliott Investment, Third Point, Bridgewater Associates, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioMarin Pharmaceuticals Inc.

BMRN Key Metrics

Key financial metrics for BMRN
Metric	Value
Price	$52.02
Market Cap	$9.60B
P/E Ratio	35.90
EPS	$1.40
Dividend Yield	0.00%
52-Week High	$73.51
52-Week Low	$49.26
Volume	1.84M
Avg Volume	0
Revenue (TTM)	$3.24B
Net Income	$268.74M
Gross Margin	76.53%

Top Hedge Funds Holding BMRN

Viking Global holds 7.06M shares of BMRN, changed +16.98% as of Mar 31, 2026.
Elliott Investment holds 3.50M shares of BMRN, changed -50.00% as of Mar 31, 2025.
Third Point holds 385.00K shares of BMRN, changed +0.00% as of Dec 31, 2023.
Bridgewater Associates holds 206.91K shares of BMRN, changed -10.02% as of Mar 31, 2026.
Redmile Group holds 173.86K shares of BMRN, changed +0.00% as of Mar 31, 2026.

Latest BMRN News

BioMarin’s BMN 401 Raises PPi Through 52 Weeks but Misses RGI-C Endpoint — May 18, 2026
BioMarin slides as higher 2026 revenue outlook comes with lower EPS guidance — May 5, 2026
BioMarin’s VOXZOGO Yields 13.6 cm Height Gain and Stable Bone Density — May 2, 2026
BioMarin Completes $4.8B Amicus Acquisition, Adds Two Lysosomal Disease Therapies — Apr 28, 2026
BioMarin slides as Roctavian exit spotlights dependence on Voxzogo growth — Apr 12, 2026

Recent BMRN Insider Trades

Friberg Gregory R sold 3.28K (~$176.68K) on May 7, 2026.
Guyer Charles Greg sold 16.49K (~$996.74K) on Mar 11, 2026.
Friberg Gregory R sold 6.33K (~$381.94K) on Feb 26, 2026.

BMRN Analyst Consensus

18 analysts cover BMRN: 0 strong buy, 13 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $89.31.

Common questions about BMRN

Who owns BMRN stock?: Hedge funds tracked by Rallies that own BMRN include Viking Global, Elliott Investment, Third Point, Bridgewater Associates, and Redmile Group. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for BioMarin Pharmaceuticals Inc.
Does Rallies show 13F holders for BMRN?: Yes. Rallies tracks hedge fund and 13F ownership data for BMRN, including fund names, share counts, latest tracked quarter, and position changes when available.
Is BMRN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BMRN. It does not provide personalized investment advice.